Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02357810 · ClinicalTrials.gov registry record · Phase 2
Pazopanib Hydrochloride and Topotecan Hydrochloride in Treating Patients With Metastatic Soft Tissue and Bone Sarcomas
A Phase 2 study of Recurrent Osteosarcoma and Recurrent Adult Soft Tissue Sarcoma, sponsored by Northwestern University.
- Completed
- Registry status
- Phase 2
- Development phase
- 178
- Enrollment target
- 8
- Study locations
NCT02357810: Completed Phase 2 study of Recurrent Osteosarcoma and Recurrent Adult Soft Tissue Sarcoma, sponsored by Northwestern University.
NCT02357810 is a Phase 2 study of Recurrent Osteosarcoma and Recurrent Adult Soft Tissue Sarcoma that has completed, run by Northwestern University. The registered enrollment target is 178 participants, above the 53-participant average among 13 other Recurrent Osteosarcoma trials with a reported enrollment target (236% higher). The trial reports 8 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02357810, a Phase 2 study of Recurrent Osteosarcoma and Recurrent Adult Soft Tissue Sarcoma, has completed, sponsored by Northwestern University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 178 participants
- Enrollment target
- 8
- Study locations
Study Summary
The purpose of this clinical research study is to learn if pazopanib when given in combination with topotecan can help to control sarcomas. The safety of this drug combination will also be studied. Pazopanib hydrochloride and topotecan hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Primary Outcome
PFS will be defined from the time of enrollment to the study until progression of disease or death from any cause, as assessed by RECIST 1.1 and measured at 12 weeks after treatment initiation for patients with STS. PFS estimates will be calculated using Kaplan-Meier methods Progression is defined as at least a 20% increase in the sum of the Longest Diameter (LD) of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new
Conditions Studied
Interventions
- OTHER Laboratory Biomarker Analysis
- DRUG Pazopanib Hydrochloride
- DRUG Oral Topotecan Hydrochloride
Study Locations (8)
Illinois
- Northwestern University - Chicago
- Northwestern University- Lake Forest Hospital - Lake Forest
Minnesota
- Masonic Cancer Center, University of Minnesota - Minneapolis
- Mayo Clinic - Rochester
Arizona
- Mayo Clinic in Arizona - Scottsdale
Florida
- Mayo Clinic in Florida - Jacksonville
Iowa
- University of Iowa Hospitals and Clinics - Iowa City
Missouri
- Washington University School of Medicine - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 178 participants |
| Start Date | 2015-03-21 |
| Est. Completion | 2021-10-12 |
| Phase | Phase 2 |
What the finished NCT02357810 record still lists
NCT02357810 is an interventional study that assigns participants to a tested intervention. The registered 178 participants enrollment target is mid-sized for trials with a published cap, above the 53-participant average among 13 other Recurrent Osteosarcoma trials with a reported enrollment target (236% higher).
The record links to 7 conditions, with Recurrent Osteosarcoma appearing as the primary indexed condition, and to 3 interventions - of which Laboratory Biomarker Analysis is the first listed.
NCT02357810 lists 8 locations in 6 states (Illinois, Minnesota, Arizona).
Frequently Asked Questions
What is clinical trial NCT02357810 about?
NCT02357810 is a clinical study titled "Pazopanib Hydrochloride and Topotecan Hydrochloride in Treating Patients With Metastatic Soft Tissue and Bone Sarcomas". The purpose of this clinical research study is to learn if pazopanib when given in combination with topotecan can help to control sarcomas. The safety of this drug combination will also be studied. Pazopanib hydrochloride and topotecan hydrochloride may stop the growth of tumor cells by blocking som...
What is the current status of trial NCT02357810?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 178 participants. The study started on 2015-03-21. Estimated completion is 2021-10-12.
What conditions does trial NCT02357810 study?
This clinical trial studies the following conditions: Recurrent Osteosarcoma, Recurrent Adult Soft Tissue Sarcoma, Metastatic Osteosarcoma, Stage IV Adult Soft Tissue Sarcoma, Recurrent Liposarcoma.
What interventions are being tested in trial NCT02357810?
The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Pazopanib Hydrochloride (DRUG), Oral Topotecan Hydrochloride (DRUG).
Who is sponsoring clinical trial NCT02357810?
This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02357810 being conducted?
This trial has 8 study locations across Arizona, Florida, Illinois, Iowa, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Recurrent Osteosarcoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02357810's enrollment target sits among peer trials
178 1st of 13 higher than 13 of 13 other Recurrent Osteosarcoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Recurrent Osteosarcoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Atezolizumab and Cabozantinib for the Treatment of Adolescents and Young Adults With Recurrent or Metastatic Osteosarcoma, TACOS Study
RECRUITING · Phase 2
-
Humanized Monoclonal Antibody 3F8 (Hu3F8) With Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) in the Treatment of Recurrent Osteosarcoma
ACTIVE NOT RECRUITING · Phase 2
-
LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas
ACTIVE NOT RECRUITING · Phase 2
-
Oleclumab and Durvalumab for the Treatment of Recurrent, Refractory, or Metastatic Sarcoma
ACTIVE NOT RECRUITING · Phase 2
-
Therapeutic Angiotensin-(1-7) in Treating Patients With Metastatic Sarcoma That Cannot Be Removed By Surgery
COMPLETED · Phase 2
-
Dinutuximab in Combination With Sargramostim in Treating Patients With Recurrent Osteosarcoma
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03642002 · 178 participants · NA
The Effects of Music Therapy on Adult Patients Requiring Mechanical Ventilation in the ICU
- NCT04227847 · 178 participants · Phase 1
A Safety Study of SEA-CD70 in Patients With Myeloid Malignancies
- NCT04855214 · 178 participants
Evaluating the Experience of Upper Limb Prosthesis Use
- NCT05391126 · 178 participants · NA
GENOCARE: A Prospective, Randomized Clinical Trial of Genotype-Guided Dosing Versus Usual Care
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI